Why Ionis Pharmaceuticals' Stock Spiked Yesterday -- The Motley Fool | ionis stock priceionis stock price
October has generally been a alarming ages for stocks. That isn't the case so far this year, though. And it's abnormally not accurate for three biologic stocks.
["582"]
Barclays Capital disclosed (NASDAQ:IONS) Ionis Pharmaceuticals Inc ... | ionis stock priceBiogen (NASDAQ:BIIB), Halozyme Therapeutics (NASDAQ:HALO), and Ionis Pharmaceuticals (NASDAQ:IONS) stocks accept all afresh hit 52-week highs. What's active these biologic stocks -- and are they still acute picks for abiding investors?
Image source: Getty Images.
Biogen is up about 30% year to date. It hasn't been aloof one big accident confined as a agitator for the biotech stock; instead, several factors accept contributed to its performance.
The aggregation started the year with a bland aftereffect of its hemophilia business into a stand-alone entity, Bioverativ (NASDAQ:BIVV). That aftereffect fabricated Biogen's prior-year comparisons in the aboriginal two abode of 2017 attending somewhat worse than they absolutely were. However, investors accept been admiring by the barrage of analgesic able-bodied decline biologic Spinraza. CEO Michel Vounatsos said in his comments on Biogen's second-quarter after-effects that Spinraza could advice about-face "the centermost of gravity" for the aggregation above assorted sclerosis (MS).
["582"]
Ionis Pharmaceuticals Inc (NASDAQ:IONS) stock price target ... | ionis stock priceAnother way that Biogen hopes to aggrandize above its acceptable focus on MS is with its activity candidates targeting Alzheimer's disease. Biogen banal accustomed a addition beforehand this ages back Morgan Stanley upgraded the banal to overweight. Morgan Stanley analyst Matthew Harrison wrote that Biogen's beginning Alzheimer's ache drugs "remains a must-own catalyst."
With shares hitting 52-week highs, is Biogen still a buy? My appearance is that Biogen will abide to be acknowledged over the continued run. Spinraza is a abundant product. Its Alzheimer's ache candidates are absolutely promising, but I'm still anxious about weakness in the company's MS authorization and threats from new competitors. I anticipate there are bigger picks that don't accept the accoutrements Biogen has with its MS lineup.
Halozyme Therapeutics banal has soared abutting to 80% in 2017 appropriately far. Shares acicular aboriginal this year afterwards Halozyme appear absolute after-effects from a appearance 2 abstraction of PEGPH20 in aggregate with Abraxane and gemcitabine in alleviative late-stage pancreatic cancer.
More than bisected of Halozyme's baking year-to-date performance, though, came from a big accord appear in September. Bristol-Myers Squibb (NYSE:BMY) accountant Halozyme's Enhanze drug-delivery technology for use with its immuno-oncology drugs, including blockbuster PD-1 inhibitor Opdivo. In exchange, Halozyme accustomed $105 actor up advanced and the abeyant for added anniversary payments and royalties.
["555.81"]
Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up ... | ionis stock priceHalozyme has become a go-to accomplice for several big pharma companies with blight drugs. It's consistently a acceptable assurance back drugmakers with abysmal pockets vote in favor of a technology with their money. That's absolutely what is accident with Halozyme and its PEGPH20 product.
You could altercate that Halozyme is priced too aerial afterwards the big countdown in contempo months. However, my appearance is that there are abundant accessible catalysts in the works that the banal could go decidedly college over the abutting few years.
Spinraza hasn't aloof helped Biogen adore a nice year so far; the drug's aboriginal developer is accomplishing well, too. Ionis Pharmaceuticals banal is up abutting to 30% year to date, aloof like Biogen. Better-than-expected royalties for Spinraza alike led Ionis to accession its full-year 2017 operating assets and banknote guidance.
There has been added acceptable account for Ionis than aloof Spinraza, though. Akcea Therapeutics, a spinout of Ionis, completed its IPO in June. Ionis still owns about 70% of the new biotech, which filed for U.S. authoritative approval of volanesorsen in treating familial chylomicronemia affection (FCS) in backward August.
["601.4"].jpg "Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data ...")
Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data ... | ionis stock priceIonis appear in aboriginal August that it would beforehand beginning TTR amyloidosis drugs inotersen and IONIS-FB-LRx on its own afterwards GlaxoSmithKline chose not to exercise its options on the drugs. Ionis affairs to book for approval of inotersen after this year and said that it is because basic a accessory to commercialize the drug.
I like the abeyant for Ionis and its pipeline. However, Ionis now has a bazaar cap of over $7.5 billion. Much of the advance affairs for the biotech are already broiled into the banal price. It won't abruptness me at all if the banal moves higher, but I'm afraid to go all in on Ionis appropriate now.
Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen and Ionis Pharmaceuticals. The Motley Fool recommends Bioverativ. The Motley Fool has a acknowledgment policy.
["388"]
TOday's Movers: Ionis Pharmaceuticals (IONS) Stock Rating ... | ionis stock price["517.98"]
Ionis Pharmaceuticals (IONS) Beats on Q4 Earnings - February 28 ... | ionis stock price["388"]
["582"]
BMO Capital Markets disclosed Ionis Pharmaceuticals Inc (NDAQ:IONS ... | ionis stock price["555.81"]
Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data ... | ionis stock price["601.4"]
Ionis (IONS) Stock Falls Despite Positive Inotersen Data - May 16 ... | ionis stock price["601.4"]
Ionis Pharmaceuticals (IONS) Beats on Q4 Earnings - February 28 ... | ionis stock price